期刊文献+

动态血压监测比较贝尼地平与氨氯地平的降压疗效和安全性 被引量:2

Efficacy of Benidipine and Amlodipine by ABPM
下载PDF
导出
摘要 目的:用动态血压监测(ABPM)的方法比较两种钙拮抗剂(贝尼地平与氨氯地平)治疗原发性高血压的疗效。方法:选择原发性高血压患者44例,随机分为贝尼地平组20例,氨氯地平组24例。分别观察服药前和服药后(8周末)的24 h、白昼、夜间及各时点的动态血压变化。结果:(1)贝尼地平组和氨氯地平组服药前后(8周末)的24h、白昼和夜间的平均收缩压/舒张压均明显下降(P均<0.05)。贝尼地平组和氨氯地平组服药后(8周末)绝大部分时点收缩压和舒张压均较服药前下降(P<0.05)。24h、白昼和夜间的平均收缩压/舒张压下降值在贝尼地平组分别为(9.52±4.21)/(6.34±3.08),(11.63±3.32)/(7.46±2.80),(5.30±2.04)/(4.11±2.40)mmHg(p<0.05);在氨氯地平组则分别为(12.36±1.99)/(7.95±1.84),(11.97±1.84)/(8.24±1.66),(12.69±2.08)/(6.90±1.34)mmHg(P<0.05)。但两组间上述指标比较无显著性差异(P>0.05)。(2)谷峰比:贝尼地平组和氨氯地平组SBP分别为:65%、95%;DBP分别为62%,69%。(3)不良反应发生率:贝尼地平组低于氨氯地平组,但两组间差异无统计学意义。结论:贝尼地平(4—8mg/d)或氨氯地平(5~10mg/d),对每日1次口服治疗原发性高血压患者均可以维持24小时平稳降压。 Objective: To compare the clinical efficacy of two calium antagonists (Benidipine and Amlodipine) on the treatment of essential hypertension using ambulatory blood pressure monitoring (ABPM). Methods: It was a randomized, double blind, single - center, controlled clinical trial. After 2 weeks of wash - out period, patients with 24h mean diastolic blood pressure (DBP) ≥ 85mmHg were randomly treated with either Benidipine 4 - 8mg/d or Amlodipine 5 - 10mg/d (once a day) for 8 weeks. The dosage was titrated at the end of the 2th week. ABPM was conducted at the end of wash - out period and 8 th week after treatment. Results: ( 1) At the end of the 8th week, In Benidipine group the mean level of SBP/DBP of 24hour, day - time and night - time dropped by (9.52±4.21)/ (6.34±3.08),(11.63±3.32)/(7.46±2.80),(5.30±2.04)/(4.11±2.40)mmHg (P < 0.05) respectively. In Amilodip-ine group the mean level of SBP/DBP of 24hour, day - time and night - time were (12.36 ±1.99) /(7.95 ± 1.84), (11. 97 ± 1.84) / (8.24± 1.66), (12.69±2.08)/(6.90± 1.34)mmHg (P<0.05), respectively. The levels of SBP/DBP were decreased at most time point of 24h - ABPM during treatment in both groups, but there was no significant difference between two groups. (2)The mean trough/peak ratio(TPR) in Benidipine group and Amilodipine group for SBP were 65% and 95% ,DBP were 62% and 69% , respectively. (3)There was a tendency that the rate of adverse reaction in Benidipine group was lower than that in Amilodipine group,but without difference significantly. Conclusion: Benidipine (4- 8mg/d, once a day) can keep the same speed to decrease blood pressure smoothly for 24hrs as Amlodipine (5 -10mg/d,once a day) .Both medicine are safe and effective in the treatment of hypertension.
出处 《中国医药导刊》 2004年第5期369-371,共3页 Chinese Journal of Medicinal Guide
关键词 氨氯地平 动态血压监测 收缩压 舒张压 服药后 降压疗效 药物临床研究 下降 平均 指标比较 Benidipine Amlodipine hypertension Ambulatory blood pressure monitoring
  • 相关文献

参考文献14

  • 1Nakajima O, Akioka H, Miyazaki M. Effect of the Calcium Antagonist Benidipine Hydrochloride on 24- h Ambulatory Blood Pressure in Patients with Mild to Moderate Hypertension in a Double - Blind Study against Placebo. Arzneimittelforschung, 2000;50(7):620
  • 2Muneta S, Kohara K, Hiwada K. Effects of benidipine hydrochloride on 24 - hour blood pressure and blood pressure response to mental stress in elderly patients with essential hypertension. Int J Clin Pharmacol Ther,1999;37(3): 141 ~ 147
  • 3TOHMS Investigation group. The Treatment of Mild Hypertension Study:A Randomized, Placebo - Controlled Trial of a Nutritional - Hygienic Regimen along with Various Drug Monotherapies. Arch Intern Med,1991,151: 1413 ~ 1423
  • 4Proposed guideline for the clinical evaluation of antihypertensive drug products(Draft) .Rockville, MD: FDA Division of Cardio-renal Drug Products: 1988: 4
  • 5Miki S. Effect of Benidipine Hydrochloride, a Ca Antagonist, on Ambulatory Blood Pressure in Patients with Essential Hypertension The Clinical Report, 1993;27:4381 - 4386
  • 6Kalke S, Shah BV, Nair KG, et al. Clinical trial of benidipine in mild to moderate hypertension. J Assoc Physicians India, 1999;47(2): 195- 1977
  • 7Ishii A, Nishida K, Oka T. Receptor Binding Properties of the New Calcium Antagonist Benidipine Hydrochloride. Arazneim. - Forsch,1988;38:1677 - 1680
  • 8Yasuaki D, Masayoshi K, Koichi S. Benidipine Improves Endothelial Function in Renal Resistance Arteries of Hypertensive Rats. Hypertension, 1996;28:58 - 63
  • 9Suzuki M, Kanazawa A, Hasegawa M, Harano Y. Improvement of insulin resistance in essential hypertension by long- acting Ca antagonist benidipine. Clin Exp Hypertens, 1999;21(8): 1327 - 1344
  • 10Yao K, Sato H, Sonoda R. Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens Res,2003; 26(7) :569- 576

二级参考文献14

  • 1[1]Anton H.van den Meiracker, Peter JJ. Admiraal,Joop A. Janssen, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist Irbesartan in hypertension. Hypertension,1995;25:22~29.
  • 2[2]Weber A. Clinical experience with the angiotensin II receptor antagonist Losartan ; a preliminary report. Am J Hypertens,1992; 5(suppl):247s~251s.
  • 3[3]Menard J, Guyene TT,Chatellier G, et al. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension, 1991;18:257~265.
  • 4[4]Lionl H.Opie. Angiotensin converting enzyme inhibitors. Author, Publishing House, New York, 1994.
  • 5[5]Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension,1993;21:704~713..
  • 6MEREDITH PA, ELLIOTT HL. FDA guidelines on trough:peak ratios in the evalu ation ofantihypertensive agents [J]. J Cardiovasc Pharmacol,1994,23 Suppl 5 : S26-S30.
  • 7PARATI G, OMBONI S, RIZZONI D. The smoothness index: a new, reproducible andclinically relevant measure of the homogeneity of the blood pressure reducti on withtreatment for hypertension[J]. J Hypertens,1998, 16(11): 1685-1691.
  • 8GROPPELLI A, OMBONI S, PARATI G. Evaluation of noninvasive blood pressuremonitoring devices spacelabs 90202 and 90207 versus resting and ambulatory 24-h ourintra-arterial blood pressure[J]. Hypertension,1992,20(2):227-232.
  • 9OMBONI S, PARATI G, ZANCHETTI A. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects[J ]. JHypertens,1995,13(10):1105-1112.
  • 10BLAND JM, ALTMAN DG. Statistical methods for assessing agreement between t womethods of clinical measurement[J]. Lancet, 1986,1(8476):307-310.

共引文献47

同被引文献32

  • 1胡景云.贝尼地平对高血压病患者的降压作用及β_2微球蛋白的影响[J].医学临床研究,2004,21(10):1167-1168. 被引量:2
  • 2康连鸣,李一石,胡大一,郭静萱,张麟,黄洁,汪芳,边文彦,王力.盐酸贝尼地平治疗原发性高血压的多中心临床研究[J].中国临床药理学杂志,2005,21(1):3-7. 被引量:14
  • 3[1]Furukawa T, Yamakawa T. Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in xenopusoocytes. J Pharmacol Exp Ther, 1999,291 ( 2 ): 464
  • 4[2]Karasawa A, Kubo K, Oka T, et al. Antihypertensive effects of intravenous administration of benidipine hydrochloride and some other calcium antagonists in conscious spontaneously hypertensive rats. Arzneimittel Forschung, 1988,38 (ⅡA): 1691
  • 5[3]Moriyama T, Karasawa A . Cardiovascular effects of beinidipine and amlodipine in isolated tissues and anesthetized dogs. Biol Pharm Bull,1994, 17(Ⅱ) :1468
  • 6[4]Karasawa A, Nomura H, Nito M, et al. Effect of benidipine hydrochloride (Coniel)on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats. Japanese journal of pharmacology, 1999,113 ( 5 ) :317
  • 7[5]Kitakaze M, Node K, Minamino T, et al. A Ca channel blocker,benidipine,increases coronary blood flow and attenuates the severity of myocardial ischema via NO - dependent mechanisms in dogs. J Am Coll Cardiol, 1999,33 (1) :242
  • 8[6]Karasawa A, Kubo K, Shuto K, et al. Beneficial effects of the new calcium antagonist benidipine hydrochloride on myocardial dysfunction following cornary occlusion and reperfusion in anesthetized dogs. Arzneimittel Forschung, 1988,38 (ⅡA): 1717
  • 9[7]Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol, 1997,30 (4) :431
  • 10[9]Higo K, Karasawa A, Kubo K. Protective effects of benidipine hydrochloride ( KW - 3049 ), a calcium antagonist experimental arterial calcinosis and endothelial dysfunction in rats. J Pharmacobiodyn, 1992,15 ( 3 ): 113

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部